Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorMAKADIA, Sunal S.-
dc.contributor.authorBLAHA, Michael-
dc.contributor.authorKEENAN, Tanya-
dc.contributor.authorNDUMELE, Chiadi-
dc.contributor.authorJONES, Steven-
dc.contributor.authorDEFILIPPIS, Andrew-
dc.contributor.authorMARTIN, Seth-
dc.contributor.authorKOHLI, Payal-
dc.contributor.authorCONCEICAO, Raquel-
dc.contributor.authorCARVALHO, Jose-
dc.contributor.authorNASIR, Khurram-
dc.contributor.authorBLUMENTHAL, Roger-
dc.contributor.authorSANTOS, Raul D.-
dc.identifier.citationAMERICAN JOURNAL OF CARDIOLOGY, v.112, n.10, p.1599-1604, 2013-
dc.description.abstractHepatic steatosis is closely associated with the metabolic syndrome. We assessed for an independent association between hepatic steatosis and atherogenic dyslipidemia after adjustment for obesity, physical activity, hyperglycemia, and systemic inflammation. We studied 6,333 asymptomatic subjects without clinical cardiovascular disease undergoing a health screen in Brazil from November 2008 to July 2010. Hepatic steatosis was diagnosed by ultrasound. Atherogenic dyslipidemia was defined using 2 definitions: criteria for (1) metabolic syndrome or (2) insulin resistance (triglyceride/high-density-lipoprotein cholesterol ratio of >= 2.5 in women and >= 3.5 in men). In hierarchical multivariate regression models, we evaluated for an independent association of hepatic steatosis with atherogenic dyslipidemia. Hepatic steatosis was detected in 36% of participants (average age 43.5 years, 79% men, average body mass index 26.3 kg/m(2)). Subjects with hepatic steatosis had similar levels of low-density lipoprotein cholesterol, with significantly lower level of high-density-lipoprotein cholesterol and higher level of triglyceride compared with those without steatosis. Hepatic steatosis remained significantly independently associated with atherogenic dyslipidemia of both definitions (metabolic syndrome [odds ratio 2.47, 95% confidence interval 2.03 to 3.02] and insulin resistance [odds ratio 2.50, 95% confidence interval 2.13 to 2.91]) after multivariate adjustment. Stratified analyses showed a persistent independent association in nonobese subjects, those without metabolic syndrome, those with normal high-sensitivity C-reactive protein, nonalcohol abusers, and those with normal liver enzymes. Hepatic steatosis was significantly associated with atherogenic dyslipidemia independent of obesity, physical activity, hyperglycemia, and systemic inflammation after multivariate adjustment. In conclusion, this adds to the growing body of evidence that hepatic steatosis may play a direct metabolic role in conferring increased cardiovascular risk.-
dc.relation.ispartofAmerican Journal of Cardiology-
dc.subject.otherfatty liver-disease-
dc.subject.otherdensity-lipoprotein cholesterol-
dc.subject.othermetabolic syndrome-
dc.titleRelation of Hepatic Steatosis to Atherogenic Dyslipidemia-
dc.subject.wosCardiac & Cardiovascular Systems-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-, Sunal S.:Johns Hopkins Med Inst, Dept Cardiol, Baltimore, MD 21205 USA-, Michael:Johns Hopkins Med Inst, Dept Cardiol, Baltimore, MD 21205 USA-, Tanya:Johns Hopkins Ciccarone Preventat Cardiol Ctr, Dept Cardiol, Baltimore, MD USA-, Chiadi:Johns Hopkins Med Inst, Dept Cardiol, Baltimore, MD 21205 USA-, Steven:Johns Hopkins Med Inst, Dept Cardiol, Baltimore, MD 21205 USA-, Andrew:Univ Louisville, Dept Cardiol, Louisville, KY 40292 USA-, Seth:Johns Hopkins Med Inst, Dept Cardiol, Baltimore, MD 21205 USA-, Payal:Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA-, Raquel:Hosp Israelita Albeit Einstein, Prevent Med Ctr, Sao Paulo, Brazil-, Jose:Hosp Israelita Albeit Einstein, Prevent Med Ctr, Sao Paulo, Brazil-, Khurram:Baptist Hlth South Florida, Ctr Prevent & Wellness, Miami, FL USA-, Roger:Johns Hopkins Med Inst, Dept Cardiol, Baltimore, MD 21205 USA-
hcfmusp.relation.referenceAdiels M, 2006, DIABETOLOGIA, V49, P755, DOI 10.1007/s00125-005-0125-z-
hcfmusp.relation.referenceAdiels M, 2008, CURR DIABETES REP, V8, P60, DOI 10.1007/s11892-008-0011-4-
hcfmusp.relation.referenceAlberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644-
hcfmusp.relation.referenceBerneis KK, 2002, J LIPID RES, V43, P1363, DOI 10.1194/jlr.R200004-JLR200-
hcfmusp.relation.referenceBlaha MJ, 2008, J CLIN LIPIDOL, V2, P267, DOI 10.1016/j.jacl.2008.06.013-
hcfmusp.relation.referenceBlake GJ, 2002, CIRCULATION, V106, P1930, DOI 10.1161/01.CIR.0000033222.75187.B9-
hcfmusp.relation.referenceBrowning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422-
hcfmusp.relation.referenceBush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789-
hcfmusp.relation.referenceChan DC, 2010, ARTERIOSCL THROM VAS, V30, P1043, DOI 10.1161/ATVBAHA.109.202275-
hcfmusp.relation.referenceCraig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB-
hcfmusp.relation.referenceCromwell William C, 2004, Curr Atheroscler Rep, V6, P381, DOI 10.1007/s11883-004-0050-5-
hcfmusp.relation.referenceDeFilippis AP, 2013, ATHEROSCLEROSIS, V227, P429, DOI 10.1016/j.atherosclerosis.2013.01.022-
hcfmusp.relation.referenceFRIEDEWA.WT, 1972, CLIN CHEM, V18, P499-
hcfmusp.relation.referenceGardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875-
hcfmusp.relation.referenceHosoyamada K, 2012, DIABETOL METAB SYNDR, V4, DOI 10.1186/1758-5996-4-34-
hcfmusp.relation.referenceJOSEPH AEA, 1991, CLIN RADIOL, V43, P26, DOI 10.1016/S0009-9260(05)80350-2-
hcfmusp.relation.referenceKotronen A, 2008, ARTERIOSCL THROM VAS, V28, P27, DOI 10.1161/ATVBAHA.107.147538-
hcfmusp.relation.referenceNdumele CE, 2011, ARTERIOSCL THROM VAS, V31, P1927, DOI 10.1161/ATVBAHA.111.228262-
hcfmusp.relation.referencePERLOFF D, 1993, CIRCULATION, V88, P2460-
hcfmusp.relation.referenceRashid S, 2003, CLIN BIOCHEM, V36, P421, DOI 10.1016/S0009-9120(03)00078-X-
hcfmusp.relation.referenceSaadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354-
hcfmusp.relation.referenceSalazar MR, 2012, AM J CARDIOL, V109, P1749, DOI 10.1016/j.amjcard.2012.02.016-
hcfmusp.relation.referenceSniderman A, 2010, NAT REV ENDOCRINOL, V6, P335, DOI 10.1038/nrendo.2010.50-
hcfmusp.relation.referenceTargher G, 2005, DIABETES, V54, P3541, DOI 10.2337/diabetes.54.12.3541-
hcfmusp.relation.referenceToledo FGS, 2006, DIABETES CARE, V29, P1845, DOI 10.2337/dc06-0455-
hcfmusp.relation.referenceZambon A, 1999, CIRCULATION, V99, P1959-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCP
Departamento de Cardio-Pneumologia - FM/MCP

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)306.08 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.